Vasohibin‐2 plays an essential role in metastasis of pancreatic ductal adenocarcinoma. Issue 7 (18th June 2019)
- Record Type:
- Journal Article
- Title:
- Vasohibin‐2 plays an essential role in metastasis of pancreatic ductal adenocarcinoma. Issue 7 (18th June 2019)
- Main Title:
- Vasohibin‐2 plays an essential role in metastasis of pancreatic ductal adenocarcinoma
- Authors:
- Iida‐Norita, Rie
Kawamura, Minaho
Suzuki, Yasuhiro
Hamada, Shin
Masamune, Atsushi
Furukawa, Toru
Sato, Yasufumi - Abstract:
- Abstract: Vasohibin‐2 (VASH2) is expressed in various cancers and promotes their progression. We recently reported that pancreatic cancer patients with higher VASH2 expression show poorer prognosis. Herein, we sought to characterize the role of VASH2 in pancreatic cancer. We used LSL‐Kras G12D ; LSL‐Trp53 R172H ; Pdx‐1‐Cre ( KPC ) mice, a mouse model of pancreatic ductal adenocarcinoma (PDAC), and cells isolated from them (KPC cells). Knockdown of Vash2 from PDAC cells did not affect their proliferation, but decreased their migration. When Vash2‐knockdown PDAC cells were orthotopically inoculated, liver metastasis and peritoneal dissemination were reduced, and the survival period was significantly prolonged. When KPC mice were crossed with Vash2 ‐deficient mice, metastasis was significantly decreased in Vash2 ‐deficient KPC mice. VASH2 was recently identified to have tubulin carboxypeptidase activity. VASH2 knockdown decreased, whereas VASH2 overexpression increased tubulin detyrosination of PDAC cells, and tubulin carboxypeptidase (TCP) inhibitor parthenolide inhibited VASH2‐induced cell migration. We next clarified its role in the tumor microenvironment. Tumor angiogenesis was significantly abrogated in vivo when VASH2 was knocked down or deleted. We further examined genes downregulated by Vash2 knockdown in KPC cells, and found chemokines and cytokines that were responsible for the recruitment of myeloid derived suppressor cells (MDSC). Indeed, MDSC were accumulated inAbstract: Vasohibin‐2 (VASH2) is expressed in various cancers and promotes their progression. We recently reported that pancreatic cancer patients with higher VASH2 expression show poorer prognosis. Herein, we sought to characterize the role of VASH2 in pancreatic cancer. We used LSL‐Kras G12D ; LSL‐Trp53 R172H ; Pdx‐1‐Cre ( KPC ) mice, a mouse model of pancreatic ductal adenocarcinoma (PDAC), and cells isolated from them (KPC cells). Knockdown of Vash2 from PDAC cells did not affect their proliferation, but decreased their migration. When Vash2‐knockdown PDAC cells were orthotopically inoculated, liver metastasis and peritoneal dissemination were reduced, and the survival period was significantly prolonged. When KPC mice were crossed with Vash2 ‐deficient mice, metastasis was significantly decreased in Vash2 ‐deficient KPC mice. VASH2 was recently identified to have tubulin carboxypeptidase activity. VASH2 knockdown decreased, whereas VASH2 overexpression increased tubulin detyrosination of PDAC cells, and tubulin carboxypeptidase (TCP) inhibitor parthenolide inhibited VASH2‐induced cell migration. We next clarified its role in the tumor microenvironment. Tumor angiogenesis was significantly abrogated in vivo when VASH2 was knocked down or deleted. We further examined genes downregulated by Vash2 knockdown in KPC cells, and found chemokines and cytokines that were responsible for the recruitment of myeloid derived suppressor cells (MDSC). Indeed, MDSC were accumulated in PDAC of KPC mice, and they were significantly decreased in Vash2 ‐deficient KPC mice. These findings suggest that VASH2 plays an essential role in the metastasis of PDAC with multiple effects on both cancer cells and the tumor microenvironment, including tubulin detyrosination, tumor angiogenesis and evasion of tumor immunity. Abstract : VASH2‐dependent increase in tubulin detyrosination directly accelerates migration of PDAC cells. In the tumor microenvironment, VASH2 promotes tumor angiogenesis as a result of paracrine activity and evasion of tumor immunity as a result of altered gene expression in PDAC cells. … (more)
- Is Part Of:
- Cancer science. Volume 110:Issue 7(2019)
- Journal:
- Cancer science
- Issue:
- Volume 110:Issue 7(2019)
- Issue Display:
- Volume 110, Issue 7 (2019)
- Year:
- 2019
- Volume:
- 110
- Issue:
- 7
- Issue Sort Value:
- 2019-0110-0007-0000
- Page Start:
- 2296
- Page End:
- 2308
- Publication Date:
- 2019-06-18
- Subjects:
- angiogenesis -- MDSC -- pancreatic ductal adenocarcinoma -- tubulin detyrosination -- vasohibin‐2
Cancer -- Periodicals
Neoplasms -- Periodicals
Research -- Periodicals
Electronic journals
616.994005 - Journal URLs:
- http://firstsearch.oclc.org ↗
http://firstsearch.oclc.org/journal=1347-9032;screen=info;ECOIP ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1349-7006 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/cas.14041 ↗
- Languages:
- English
- ISSNs:
- 1347-9032
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3046.603000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 17771.xml